187 related articles for article (PubMed ID: 32532598)
1. Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancreatic cancer.
Kang J; Lee SH; Choi JH; Paik WH; Ahn DW; Jeong JB; Ryu JK; Kim YT
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):590-595. PubMed ID: 32532598
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Endoscopic Radiofrequency Ablation of Biliary Malignant Strictures in Pancreatic Cancer Suggests Potential Survival Benefit.
Kallis Y; Phillips N; Steel A; Kaltsidis H; Vlavianos P; Habib N; Westaby D
Dig Dis Sci; 2015 Nov; 60(11):3449-55. PubMed ID: 26038094
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of metallic stent for unresectable distal malignant biliary obstruction in elderly patients.
Sakai Y; Iwai T; Shimura K; Gon K; Koizumi K; Ijima M; Chiba K; Nakatani S; Sugiyama H; Tsuyuguchi T; Kamisawa T; Maetani I; Kida M
World J Gastroenterol; 2018 Jan; 24(1):69-75. PubMed ID: 29358883
[TBL] [Abstract][Full Text] [Related]
4. Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial.
Kitano M; Yamashita Y; Tanaka K; Konishi H; Yazumi S; Nakai Y; Nishiyama O; Uehara H; Mitoro A; Sanuki T; Takaoka M; Koshitani T; Arisaka Y; Shiba M; Hoki N; Sato H; Sasaki Y; Sato M; Hasegawa K; Kawabata H; Okabe Y; Mukai H
Am J Gastroenterol; 2013 Nov; 108(11):1713-22. PubMed ID: 24042190
[TBL] [Abstract][Full Text] [Related]
5. Management of occluded self-expanding biliary metal stents in malignant biliary disease.
Nennstiel S; Tschurtschenthaler I; Neu B; Algül H; Bajbouj M; Schmid RM; von Delius S; Weber A
Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):49-54. PubMed ID: 29428104
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
Templeton S; Moser M; Wall C; Shaw J; Chalchal H; Luo Y; Zaidi A; Ahmed S
J Gastrointest Cancer; 2021 Jun; 52(2):529-535. PubMed ID: 32440849
[TBL] [Abstract][Full Text] [Related]
7. Self-expandable metallic stents for malignant biliary obstruction with an anomalous pancreaticobiliary junction.
Kogure H; Tsujino T; Yagioka H; Sasaki T; Nakai Y; Hirano K; Sasahira N; Isayama H; Tada M; Kawabe T; Omata M
Surg Endosc; 2008 Mar; 22(3):787-91. PubMed ID: 17704880
[TBL] [Abstract][Full Text] [Related]
8. Nitinol versus steel partially covered self-expandable metal stent for malignant distal biliary obstruction: a randomized trial.
Soderlund C; Linder S; Bergenzaun PE; Grape T; Hakansson HO; Kilander A; Lindell G; Ljungman M; Ohlin B; Nielsen J; Rudberg C; Stotzer PO; Svartholm E; Toth E; Frozanpor F
Endoscopy; 2014 Nov; 46(11):941-8. PubMed ID: 25321620
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
McAndrew EN; Zhang H; Lambert P; Rittberg R; Dawe DE; Kim CA
Am J Clin Oncol; 2022 Feb; 45(2):55-60. PubMed ID: 35073280
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A
Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834
[TBL] [Abstract][Full Text] [Related]
11. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of chemotherapy after endoscopic double stenting for malignant duodenal and biliary obstructions in patients with advanced pancreatic cancer: a single-institution retrospective analysis.
Matsumoto K; Kato H; Horiguchi S; Tsutsumi K; Saragai Y; Takada S; Mizukawa S; Muro S; Uchida D; Tomoda T; Okada H
BMC Gastroenterol; 2018 Oct; 18(1):157. PubMed ID: 30367599
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas.
Maire F; Hammel P; Ponsot P; Aubert A; O'Toole D; Hentic O; Levy P; Ruszniewski P
Am J Gastroenterol; 2006 Apr; 101(4):735-42. PubMed ID: 16635221
[TBL] [Abstract][Full Text] [Related]
14. Expandable metal biliary stenting in patients with recurrent premature polyethylene stent occlusion.
Menon K; Romagnuolo J; Barkun AN
Am J Gastroenterol; 2001 May; 96(5):1435-40. PubMed ID: 11374679
[TBL] [Abstract][Full Text] [Related]
15. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.
Mizrahi JD; Rogers JE; Hess KR; Wolff RA; Varadhachary GR; Javle MM; Shroff RT; Ho L; Fogelman DR; Raghav KPS; Overman MJ; Pant S
Pancreatology; 2020 Apr; 20(3):501-504. PubMed ID: 31932214
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a fully covered self-expanding metal stent with flared ends in malignant biliary obstruction: a multicenter study.
Kahaleh M; Talreja JP; Loren DE; Kowalski TE; Poneros JM; Degaetani M; Raijman I; Sejpal DV; Patel S; Rosenkranz L; McNamara KN; Brijbassie A; Wang AY; Gaidhane M; Sethi A; Stevens PD
J Clin Gastroenterol; 2013; 47(10):e96-100. PubMed ID: 23933803
[TBL] [Abstract][Full Text] [Related]
17. Partially covered metal stents have longer patency than uncovered and fully covered metal stents in the management of distal malignant biliary obstruction: a retrospective study.
Yokota Y; Fukasawa M; Takano S; Kadokura M; Shindo H; Takahashi E; Hirose S; Kawakami S; Fukasawa Y; Sato T; Enomoto N
BMC Gastroenterol; 2017 Oct; 17(1):105. PubMed ID: 29020933
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of the WallFlex partially covered stent for unresectable malignant biliary obstruction: a multicenter single-arm prospective study.
Sakai Y; Tsuyuguchi T; Hirata N; Sugiyama H; Shimura K; Nakaji S; Shiratori T; Fujimoto T; Tsuchiya S; Mikami S; Yokosuka O
Hepatogastroenterology; 2013; 60(128):1854-60. PubMed ID: 24088309
[TBL] [Abstract][Full Text] [Related]
19. Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer.
Kayahan N; Karaca M; Satış H; Yapar D; Özet A
Turk J Med Sci; 2021 Aug; 51(4):1727-1732. PubMed ID: 33315355
[TBL] [Abstract][Full Text] [Related]
20. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer.
Keum J; Lee HS; Kang H; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Bang S
Cancer Chemother Pharmacol; 2020 Apr; 85(4):651-659. PubMed ID: 32185483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
